Author: Admin

Developer

Release – CanAlaska Promotes Cory Belyk to CEO and Executive Vice President

Posted on by Admin


CanAlaska Promotes Cory Belyk to CEO & Executive Vice President

 

Vancouver, Canada, May 25, 2021 – CanAlaska Uranium Ltd. (TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) (“CanAlaska” or the “Company”) is pleased to announce the promotion of Cory Belyk to Chief Executive Officer and Executive Vice President of the Company effective June 1, 2021. Peter Dasler will continue as President of CanAlaska, working closely with Cory Belyk to grow the Company. The rapid resurgence of interest in the uranium market has accelerated the Company’s activities including the addition of new exploration geologists. Cory Belyk now heads CanAlaska’s exploration and management teams, based from the Company’s office in Saskatoon, Saskatchewan.

Cory Belyk is a professional geologist with nearly 30 years of experience working for major and junior mining companies in the Athabasca Basin and worldwide. Prior to joining CanAlaska in 2019 as Chief Operating Officer, he was Director of Exploration for Cameco’s international operations including Mongolia and Australia. Mr. Belyk was also a member of Cameco’s exploration management team during the Fox Lake and West McArthur uranium discoveries in Saskatchewan. Mr. Belyk holds a Bachelor’s (1994) degree in Geology from the University of Saskatchewan and a Certificate in Negotiation from Harvard Law School (2014). He is a registered member of the Association of Professional Engineers and Geoscientists of Saskatchewan.

Cory Belyk, Chief Executive Officer, comments: “It is a privilege and honor to be asked to lead CanAlaska into the future. CanAlaska is a very well-structured Company with a portfolio of uranium and nickel projects that are truly world-class and ripe for additional major discoveries.  This is at a time when the world is waking up to nuclear power generation as a carbon-free source of baseload energy. Through deliberate and diligent leadership and management, CanAlaska has preserved its vast portfolio of under-explored Athabasca Basin assets and made a significant new uranium discovery next door to the world’s richest uranium mine.  In addition, new uranium and sulphide nickel projects have been added to build value for shareholders. CanAlaska’s project pipeline offers our shareholders multiple opportunities for discovery and I believe whole-heartedly further discovery is just around the corner. I commend Peter, the Board of Directors, and the CanAlaska team for their effort to build this Company to what it is today, ready for the energy needs of the present and future. I am humbled to be entrusted with the reins.”

CanAlaska President, Peter Dasler, comments; “Cory and I have worked shoulder to shoulder with our team for the past 3 years and it is a pleasure to see the significant increase in the Company’s value for our shareholders. I am very excited about CanAlaska’s opportunities for discovery at a time when we see recognition from the market of the value of uranium for carbon-free energy supply. Recent family events are now affecting the amount of time that I can spend on Company affairs and my best role will be in management support of Cory and our expanding exploration team at a time when we expect to see rapid further growth. Our new Saskatoon office is allowing us to grow to suit the market and position us for new discoveries. Cory and I look forward to new discoveries and continuing our Prospect Generator/Joint Venture strategy.”

About CanAlaska Uranium

CanAlaska Uranium Ltd. (TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) holds interests in approximately 214,000 hectares (530,000 acres), in Canada’s Athabasca Basin – the “Saudi Arabia of Uranium.”  CanAlaska’s strategic holdings have attracted major international mining companies. CanAlaska is currently working with Cameco and Denison at two of the Company’s properties in the Eastern Athabasca Basin. CanAlaska is a project generator positioned for discovery success in the world’s richest uranium district. The Company also holds properties prospective for nickel, copper, gold and diamonds.

For further information visit www.canalaska.com.

On behalf of the Board of Directors

“Peter Dasler”
Peter Dasler, M.Sc., P.Geo.
President & CEO
CanAlaska Uranium Ltd.

Contacts:

Peter Dasler, President
Tel: +1.604.688.3211 x 138
Email: [email protected]

Cory Belyk, CEO and Executive Vice President
Tel: +1.604.688.3211 x 138
Email: [email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information

All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Release – Chakana Advances Resource Definition Drilling With Multiple High-Grade Intercepts

Posted on by Admin


Chakana Advances Resource Definition Drilling With Multiple High-Grade Intercepts

 

Soledad Project Highlights Include:

  • Huancarama East – four holes with high-grade intercepts, including 134.3m of 0.92 g/t Au, 0.86% Cu, and 80.7 g/t Ag (2.15% Cu-eq) from 119.7m depth;
  • Paloma East – five holes with strong grades, including 126.1m of 0.91 g/t Au, 0.20% Cu, and 11.6 g/t Ag (0.89% Cu-eq) starting at surface;
  • Paloma West – two holes with high grades, including 101.0m of 0.53 g/t Au, 1.01% Cu, and 41.5 g/t Ag (1.71% Cu-eq) starting at surface.

Vancouver, B.C., May 25, 2021 – Chakana Copper Corp. (TSX-V: PERU; OTCQB: CHKKF; FRA: 1ZX) (the “Company” or “Chakana”), is pleased to provide results from eleven in-fill holes totaling 2,873.7m from the Huancarama, Paloma East, and Paloma West tourmaline breccia pipe discoveries at its Soledad project, Ancash, Peru (Table 1). Drilling continues as part of a fully-funded 26,000m exploration and resource drilling program planned for 2021 (Fig. 1).

David Kelley, President and CEO commented, “The resource definition drilling portion of our current program is going exceptionally well with excellent results from the three discoveries at Soledad since the resumption of drilling in 2020. Huancarama and Paloma West continue to demonstrate their high-grade nature, and strong grades were also encountered at Paloma East. Mineralization in all three breccia pipes starts at surface and is open at depth. These results are another positive step toward our resource estimate due out later this year that will include multiple breccia pipes. To date, we have only tested 15 out of the 110 total targets on the property.”

Resource Definition Drilling

Table 1. Mineralized intervals from resource definition drilling at Huancarama, Paloma East, and Paloma West.

DDH # FROM     –     TO (M) CORE LENGTH (M) AU
G/T		 AG
G/T		 CU % CU-EQ
%*		 AU-EQ G/T*
Huancarama East
SDH21-189  119.70  254.00  134.30  0.92  80.7 0.86 2.15 3.29
and 271.00  310.00  39.00  0.61  52.4 0.88 1.73 2.64
SDH21-193  29.20  38.80  9.60  1.35  78.8     2.38
and 110.00 273.00 163.00 0.26 20.1 0.43 0.77 1.18
SDH21-194 21.90 25.70 3.80 0.17 77.3 0.23 1.00 1.53
and 120.00 244.00 124.00 0.33 29.5 0.63 1.10 1.68
and 301.00  308.10  7.10  1.81  36.7 0.81 2.31 3.53
SDH21-198  144.00  210.00  66.00  0.99  82.6 1.01 2.36 3.62
including 166.00 197.00 31.00 1.46 149.9 1.77 4.01 6.13
Paloma East
SDH21-190 0.00 126.10 126.10 0.91 11.6 0.20 0.89 1.37
including 21.00 38.00 17.00 5.09 15.7     5.30
SDH21-191 0.00 99.40 99.40 0.62 12.5 0.31 0.82 1.26
and 144.00 198.70 54.70 0.16 13.9 0.22 0.44 0.68
SDH21-192 64.90 124.00 59.10 0.27 7.5 0.42 0.66 1.01
and 198.00 224.00 26.00 0.21 33.3     0.65
SDH21-195 53.00 121.00 68.00 0.28 7.3 0.31 0.56 0.85
SDH21-196 67.00 121.00 54.00 0.20 9.0 0.74 0.95 1.45
Paloma West
SDH21-197 27.00 84.80 57.80 0.53 69.4 1.17 2.11 3.23
including 28.20 49.00 20.80 1.06 183.8 2.32 4.58 7.01
SDH21-199 0.00 101.00 101.00 0.53 41.5 1.01 1.71 2.62
including 31.25 50.00 18.75 1.07 141.8 3.29 5.20 7.96

* Cu_eq and Au_eq values were calculated using copper, gold, and silver. Metal prices utilized for the calculations are Cu – US$2.90/lb, Au – US$1,300/oz, and Ag – US$17/oz. No adjustments were made for recovery as the project is an early-stage exploration project and metallurgical data to allow for estimation of recoveries are not yet available. The formulas utilized to calculate equivalent values are Cu-eq (%) = Cu% + (Au g/t * 0.6556) + (Ag g/t * 0.00857) and Au-eq (g/t) = Au g/t + (Cu% * 1.5296) + (Ag g/t * 0.01307).

Huancarama East

Four holes were drilled through the Huancarama East breccia pipe from step-out platforms (Figs. 2 and 3). One hole was drilled to the northeast, and three holes were drilled from east to west. All four holes intersected mineralized breccia, consistent with previous exploration holes (see news releases dated January 12, January 25, February 9, March 3, and April 28, 2021) with depths ranging between approximately 80m to 300m below surface. The breccia pipe has approximate lateral dimensions of 100m by 60m and is open at depth. Additional infill holes have been drilled, with more planned once assay results have been received.  Examples of mineralized drill core from these holes are shown in Figure 4.

Paloma East and Paloma West

The Paloma breccia pipes are located 300m north of Huancarama and are partially exposed at surface (Fig. 3). Five holes were drilled at Paloma East. Three holes were collared on the west side of the breccia pipe and drilled to the east, northeast, and southeast, and two holes were drilled from the north side of the exposed breccia pipe and oriented southwest and south. Mineralization was encountered in all five drill holes over a vertical range from surface to approximately 200m depth. Two resource definition holes were drilled at Paloma West from a platform on the northeast side of the exposed breccia pipe and drilled to the southwest. High-grade mineralization was intersected in both drill holes with depths ranging between approximately 20m to 80m below surface. Breccia in both pipes is open at depth and results presented here are consistent with previously reported results (see news releases dated September 17, October 26, November 18, December 3, and December 16, 2020; and April 28, 2021). Additional infill holes have been drilled at Paloma West with results pending.  Examples of mineralized drill core from these holes are shown in Figure 4.

2021 Resource and Exploration Drill Program

Results reported here are part of the fully funded 2021 drill program of 26,000m.  Combined with the drilling in the second half of 2020, approximately 32,000m is anticipated through 2021. Of this, 13,946.2m have been reported in 67 drill holes for the Paloma and Huancarama areas.  Within the 26,000m of drilling planned in 2021, the Company will complete approximately 16,000m of resource definition in-fill drilling. The results of this drill program are important to increase confidence in the resource estimate, anticipated later in 2021.

Additionally, 10,000m of exploration drilling is planned for 2021. This will focus on new targets located in the northern portion of the project that have not been drilled previously but are strategic to any eventual development at Soledad. Exploration targets have been ranked based on their technical merit, access, and logistics.

About Chakana Copper

Chakana Copper Corp is a Canadian-based minerals exploration company that is currently advancing the Soledad Project located in the Ancash region of Peru, a highly favorable mining jurisdiction with supportive communities. The Soledad Project consists of high-grade gold-copper-silver mineralization hosted in tourmaline breccia pipes. A total of 47,736 metres of exploration and resource definition drilling has been completed to date, testing 15 of 110 total exploration targets, confirming that Soledad is a large, well-endowed mineral system with strong exploration upside.  Chakana’s investors are uniquely positioned as the Soledad Project provides exposure to several metals including copper, gold, and silver. For more information on the Soledad project, please visit the website at www.chakanacopper.com.

Sampling and Analytical Procedures

Chakana follows rigorous sampling and analytical protocols that meet or exceed industry standards. Core samples are stored in a secured area until transport in batches to the ALS facility in Callao, Lima, Peru.  Sample batches include certified reference materials, blank, and duplicate samples that are then processed under the control of ALS. All samples are analyzed using the ME-MS41 (ICP technique that provides a comprehensive multi-element overview of the rock geochemistry), while gold is analyzed by AA24 and GRA22 when values exceed 10 g/t by AA24.  Over limit silver, copper, lead and zinc are analyzed using the OG-46 procedure. Soil samples are analyzed by 4-acid (ME-MS61) and for gold by Fire Assay on a 30g sample (Au-ICP21).

Results of previous drilling and additional information concerning the Project, including a technical report prepared in accordance with National Instrument 43-101, are made available on Chakana’s SEDAR profile at www.sedar.com.

Qualified Person
David Kelley, an officer and a director of Chakana, and a Qualified Person as defined by NI 43-101, reviewed and approved the technical information in this news release.

ON BEHALF OF THE BOARD
(signed) “David Kelley”
David Kelley
President and CEO

For further information contact:
Joanne Jobin, Investor Relations Officer
Phone:   647 964 0292
Email:    [email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking Statement Advisory: This release may contain forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of Chakana to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Forward looking statements or information relates to, among other things, the interpretation of the nature of the mineralization at the Soledad copper-gold-silver project (the “Project”), the potential to expand the mineralization, and to develop and grow a resource within the Project, the planning for further exploration work, the ability to de-risk the potential exploration targets, and our belief in the potential for mineralization within unexplored parts of the Project. These forward-looking statements are based on management’s current expectations and beliefs but given the uncertainties, assumptions and risks, readers are cautioned not to place undue reliance on such forward- looking statements or information. The Company disclaims any obligation to update, or to publicly announce, any such statements, events or developments except as required by law.


Figure 1 – View looking north showing breccia pipes and occurrences within the northern Soledad cluster. Pipes that have been drilled in previous campaigns are shown in red. Outcropping breccia pipes shown in green are the focus of the current drill campaign. Other pipes and occurrences remain to be tested by drilling. Additional breccia pipes occur on the south half of the property and are not shown here.  


Figure 2 – Map of Paloma and the Huancarama Breccia Complex showing drill holes reported in this release, outcropping tourmaline breccias (dark red shapes), and modeled breccia pipes (light red shapes) based on all drill holes (previous drilling shown by dark gray traces). Light gray contours are 10m interval. Untested outcropping targets are also shown. Location of section line (A-A’) for Figure 3 indicated.


Figure 3 – Isometric view looking west highlighting the drill holes at Huancarama and Paloma reported in this release. Light red 3D shapes show preliminary shape of breccias based on all drill holes (see Figure 2).

Figure 4 – Select core photos from Huancarama, Paloma East, and Paloma West reported in this release: SDH21-189 (126.2m) mosaic and jigsaw tourmaline breccia with sulfide cement; SDH21-194 (125.15m) mosaic breccia with selective clast replacement by chalcopyrite and pyrite; SDH21-194 306.75m tourmaline breccia with late chalcopyrite replacement along vein; SDH21-190 (76.72m) tourmaline breccia with chalcopyrite filling open space; SDG21-190 (110.80) shingle breccia with selective chalcopyrite replacement of shingle clasts; SDH21-197 (42.8m) mosaic tourmaline breccia with selective clast replacement and open space filling by chalcopyrite and pyrite. Core diameter is 6.35cm (HQ) in all instances.

Supermoon Red Blood Lunar Eclipse Its all Happening Tonight – Here is what it Means

Posted on by Admin 

image credit: Tomruen/WikimediaCommons, CC BY-SA


Supermoon! Red Blood Lunar Eclipse! It’s all Happening Tonight – Here is what it Means

 

The first lunar eclipse of 2021 is going to happen during the early hours of May 26. But this is going to be an especially super lunar event, as it will be a supermoon, a lunar eclipse and a red blood moon all at once. So what does this all mean?

The Moon appears 12% bigger when it is closest to Earth compared with its appearance when it’s farthest away

 

What’s a super moon?

A supermoon occurs when a full or new moon coincides with the Moon’s closest approach to the Earth.

The Moon’s orbit is not a perfect circle as it slowly rotates around Earth. Rfassbind/WikimediaCommons

The Moon’s orbit around Earth is not perfectly circular. This means the Moon’s distance from Earth varies as it goes around the planet. The closest point in the orbit, called the perigee, is roughly 28,000 miles closer to Earth than the farthest point of the orbit. A full moon that happens near the perigee is called a supermoon.

So why is it super? The relatively close proximity of the Moon makes it seem a little bit bigger and brighter than usual, though the difference between a supermoon and a normal moon is usually hard to notice unless you’re looking at two pictures side by side.

The phases of the Moon correspond to how much of the lit–up side you can see from Earth. Orion 8/WikimediaCommons, CC BY-SA

 

How does a lunar eclipse work?

A lunar eclipse happens when the Earth’s shadow covers all or part of the Moon. This can only happen during a full moon, so first, it helps to understand what makes a full moon.

Like the Earth, half of the Moon is illuminated by the sun at any one time. A full moon happens when the Moon and the Sun are on opposite sides of the Earth. This allows you see the entire lit-up side, which looks like a round disc in the night sky.

If the Moon had a totally flat orbit, every full moon would be a lunar eclipse. But the Moon’s orbit is tilted by about 5 degrees relative to Earth’s orbit. So, most of the time a full moon ends up a little above or below the shadow cast by the Earth.

A lunar eclipse occurs when the Moon passes through Earth’s shadow. Sagredo/WikimediaCommons

But twice in each lunar orbit, the Moon is on the same horizontal plane as both the Earth and Sun. If this corresponds to a full moon, the Sun, the Earth and the Moon will form a straight line and the Moon will pass through the Earth’s shadow. This results in a total lunar eclipse.

To see a lunar eclipse, you need to be on the night side of the Earth while the Moon passes through the shadow. The best place to see the eclipse on May 26, 2021, will be the middle of the Pacific Ocean, Australia, the East Coast of Asia and the West Coast of the Americas. It will be visible on the eastern half of the U.S., but only the very earliest stages before the Moon sets.

The Earth’s atmosphere gives the Moon a blood-red glow during total lunar eclipses. Irvin Calicut/WikimediaCommons, CC BY-SA

 

Why does the moon look red?

When the Moon is completely covered by Earth’s shadow it will darken, but doesn’t go completely black. Instead, it takes on a red color, which is why total lunar eclipses are sometimes called red or blood moons.

Sunlight contains all colors of visible light. The particles of gas that make up Earth’s atmosphere are more likely to scatter blue wavelengths of light while redder wavelengths pass through. This is called Rayleigh scattering, and it’s why the sky is blue and sunrises and sunsets are often red.

In the case of a lunar eclipse, red light can pass through the Earth’s atmosphere and is refracted – or bent – toward the Moon, while blue light is filtered out. This leaves the moon with a pale reddish hue during an eclipse.

Hopefully you will be able to go see this super lunar eclipse. When you do, now you will know exactly what makes for such a special sight.

 

This article was republished with permission from The
Conversation, a news
site dedicated to sharing ideas from academic experts.  Written by Shannon Schmoll Director, Abrams Planetarium, Department of Physics and Astronomy, Michigan State University

 

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Namaste Technologies Announces Phyto Extractions Shatter Now Available Nationally For Medical Consumers

Posted on by Admin


Namaste Technologies Announces Phyto Extractions Shatter Now Available Nationally For Medical Consumers

 

TORONTO, May 25, 2021 (GLOBE NEWSWIRE) — Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) a marketplace platform for cannabis and wellness products, is excited to announce that the Company’s subsidiary, CannMart Inc., holder of exclusive distribution rights to all Phyto Extractions™ products, is now distributing Phyto Extractions’ well known shatter products nationally for its medical consumers at CannMart.com, and distribution to recreational consumers via anticipated future sales to provincial monopoly wholesalers. This new launch will provide patients through CannMart.com the opportunity to purchase Phyto Extractions’ latest shatter product line in three strain varieties: Pink Kush, Blue Gorilla OG and D. Bubba, offering Canadians the opportunity of a renewed experience in the limited shatter offerings currently available in Canada. CannMart medical patients are easily able to purchase Phyto Extractions products from the comfort of their home and have them delivered directly to their door once they have received their medical document.

“We are pleased to offer cannabis consumers high quality shatter products from Phyto,” said Meni Morim, CEO of Namaste. “Shatter is a specialized subcategory of concentrate products, which is currently underserved, and has higher margins. The Phyto brand carries significant legacy cache when it comes to this subcategory, all combined, making this product expansion a compelling growth opportunity. While these products are available now for medical customers, we expect them to be available on the recreational market shortly. We have already received confirmations and approvals for SKUs in hand and purchase orders in process of finalization with certain provinces – all wanting this new product line available for their consumers.”

Phyto Extractions’ shatter is a well-known cannabis extract in its purest form, with over 70% THC, negligible CBD content, and a distinguishing effect that is said to outperform other extracts. Extracted with butane to preserve cannabis terpenes, both shatter’s fast-acting onset and natural derived terpenes that maintain and enhance the natural flavour of the extracted plant are unique selling points that are highly regarded by medical and recreational consumers. These products are anticipated to be available shortly via CannMart’s wholesale distribution channel in Alberta, Saskatchewan, Manitoba, British Columbia and Ontario to recreational customers, looking for a desirable experience with cannabis concentrates.

Producing pure extracts such as shatter, must be conducted in a controlled laboratory environment with strict safety measures. Phyto Extractions has recently upgraded its facility with the new ExtractionTek Solutions MeP XT70 hydrocarbon extraction system to ensure all shatter products are pure, safe and consistent with unmatched quality to maximize the consumer experience. For more information on how shatter is made, watch Phyto Extractions facility tour and shatter production process: https://youtu.be/bMz4V_WVoLI

About Phyto Extractions™

Phyto Extractions™ is an agricultural-scale cannabis extraction, distillation and product manufacturer located in Langley, BC at its co-located Health Canada Licensed Standard Processing (extraction and products, no cultivation), Sales (extracts, topicals, and edibles), and R&D through Adastra Labs Inc. and Analytical Testing Laboratory through Chemia Analytics Inc.

About Namaste Technologies Inc.

Headquartered in Toronto, Canada, Namaste Technologies is a marketplace platform for cannabis and wellness products. At CannMart.com, the Company provides Canadian medical customers with a diverse selection of hand-picked products from a multitude of federally licensed cultivators and US customers with access to hemp-derived CBD and smoking accessories. The Company also distributes licensed and in-house branded cannabis and cannabis derived products in Canada through a number of provincial government control boards and retailing bodies and facilitates licensed cannabis retailer sales online in Saskatchewan. Namaste’s global technology and continuous innovation address local needs in a burgeoning cannabis industry requiring smart solutions.

Information on the Company and its many products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

Cannmart.com

For more information please contact:
Namaste Technologies Inc.
Meni Morim, CEO
Edward Miller, VP Investor Relations
Ph: 647-362-0390
Email: [email protected]

Source: Namaste Technologies Inc

FORWARD-LOOKING INFORMATION – This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen.

The forward-looking information contained herein, including, without limitation, statements related to distribution of products on cannmart.com and through CannMart provincial buyers are made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made, including, without limitation, CannMart Inc.’s ability to finalize and fulfill purchase orders for shatter products, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: regulatory risk, risks relating to the Company’s ability to execute its business strategy and the benefits realizable therefrom and risks specifically related to the Company’s operations. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Source: Namaste Technologies Inc.

Esports Entertainment Group (GMBL) – Jersey Shores Up Its Gambling Strategy

Posted on by Admin

Tuesday, May 25, 2021

Esports Entertainment Group, Inc. (GMBL)
Jersey Shores Up Its Gambling Strategy

Esports Entertainment Group Inc is a development-stage online gambling company focused purely on esports. The company’s principal business operations include design, develop and test wagering systems.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New Jersey accepts gaming license. The company received the long-awaited, approval from New Jersey Division of Gaming Enforcement of its gaming license. While the approval does not distinguish between sports and esports betting, the company entered its application with one of the largest states for gambling in an effort to become the preeminent platform for esports betting.

    Next steps.  The company’s Vie gambling software platform will go through regulatory testing labs to determine if the software is compliant and meets regulatory standards. The testing could take approximately 3 to 10 weeks. Once the software is audited, the company could then be granted a transactional waiver. This will allow it to be in business and for customers to begin placing bets as soon as …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award

Posted on by Admin


The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award

 

BOCA RATON, Fla.–(BUSINESS WIRE)–May 24, 2021– 
TherapeuticsMD, Inc. (NASDAQ: TXMD), has been awarded a Top Workplaces 2021 honor by 
The Sun Sentinel. The list is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner Energage, LLC. The anonymous survey uniquely measures 15 culture drivers that are critical to the success of any organization including alignment, execution, and connection.

“During this very challenging time, Top Workplaces has proven to be a beacon of light for organizations, as well as a sign of resiliency and strong business performance,” said  Eric Rubino, Energage CEO. “When you give your employees a voice, you come together to navigate challenges and shape your path forward. Top Workplaces draw on real-time insights into what works best for their organization, so they can make informed decisions that have a positive impact on their people and their business.”

“I’m incredibly proud of the employees in the 
TherapeuticsMD family. Winning this amazing award is a testament to the culture we have built and maintain– entrepreneurial, respectful, focused on success, and dedicated to our mission of advancing women’s health and improving therapeutic options for women,” said  Robert G. Finizio, Chief Executive Officer of 
TherapeuticsMD. “Getting through these difficult pandemic months has made us all appreciate the value of working with purpose and working together to create a great future for our organization.”

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about 
TherapeuticsMD, please visit therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: 
TherapeuticsMD.

About Energage

Making the world a better place to work together.™

Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 14 years of culture research and the results from 23 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit energage.com or topworkplaces.com.

Forward-Looking Statements

This press release by 
TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the 
Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; whether the company will be able to successfully divest its vitaCare business and how the proceeds that may be generated by any such divestiture will be utilized; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; whether the FDA will approve the lower dose of BIJUVA; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership.

Investor Contacts
Nichol Ochsner
Vice President, Investor Relations
561-961-1900, ext. 2088
[email protected]

In-Site Communications, Inc.
Lisa M. Wilson
212-452-2793
[email protected]

Media Contact
Kristen Landon
Vice President, 
Marketing and Corporate Communications
561-961-1900
[email protected]

Source: 
TherapeuticsMD, Inc.

Cells that Can be Produced from Stem Cells

Posted on by Admin 

image credit: EUSKALANATO (Flickr)


What Cells Can be Made from Stem Cells?

 

Ever since the discovery of pluripotent stem cells (PSCs) more than 50 years ago and the isolation of the first-ever human embryonic stem cells (hESCs) about 20 years back, great advances have been made in the field of stem cell research. This has prompted the concept of directed differentiation, which now allows PSCs to be transformed into different tissue-specific cell types in vitro by carefully guiding and directing cells to adopt various cellular identities.

The transformation of the cells is usually done directly by either introducing specific transcription factors to PSCs, or indirectly by manipulating an amalgamation of signaling pathways that govern the expression of these transcription factors (by way of small molecules or signaling proteins). Regardless of the technique, the outcome is to faithfully recapitulate the complexities of in vivo development to drive PSCs to develop and differentiate into different cell fates.

Because PSCs are able to self-renew, they can expand and proliferate while maintaining pluripotency. This allows the ability to continuously differentiate and produce large quantities of different cell types, opening up doors to cellular transplantation therapies for the treatment of chronic diseases.

What cells can be made from stem cells in the lab? The last decade has seen an explosion of research that focuses on formulating strategies to direct differentiation of PSCs to all kinds of tissue cell types – from neurons to pancreatic beta cells, and even liver cells. One of the most common methodologies used is to perform step-wise differentiation where PSCs are directed to follow a certain developmental trajectory one stage at a time.

 

Brain

To create functional and mature neurons from human PSCs (hPSCs), hPSCs must first be differentiated into the neuroectoderm lineage and neural progenitor cells (NPCs). This can be achieved by an efficient and simple dual SMAD inhibition method described by Chambers et al. in 2009 [1]. NPCs can then be directed to develop into specific neurons through different combinations of signals [2,3]. At the end of the process, the differentiated neurons will express neuronal markers such as TUJ1 and MAP2 and some PSC-derived neurons can even produce electrophysiological responses [4]. Gunhanlar et al. (2018) described a method to differentiate induced human PSCs (iPSCs) into cortical-lineage neuronal network composed of both neurons and astrocytes that originate from a common forebrain neural progenitor [5]. The differentiated neurons display mature electrophysiological properties just like neurons in the body, such as resting membrane potential and action potential. Researchers have also devised a method to generate ‘mini-brains’ from PSCs. A protocol described by Lancaster & Knoblich (2014) differentiates hPSCs in a step-wise fashion into cerebral organoids that exhibit spatial organization (like the brain) and stains for brain regions such as forebrain, choroid plexus, and hippocampus [6].

 

Lungs

Jacob et al.’s (2017) protocol allows for the generation of functional lung alveolar epithelial type 2 (AT2) cells that produce Surfactant Protein C (STPC), a hydrophobic surfactant protein that is produced specifically by AT2 cells [7]. In 3D cultures, these cells are even able to form monolayered epithelial ‘alveolospheres’. Miller et al. (2019) published a method on generating lung organoids from hPSCs by first patterning hPSCs to ventral-foregut spheroids and then to human lung organoids [8]. At the end of the differentiation process, the lung organoids contain structures resembling bronchi surrounded by mesenchymal cells and both AT1 and AT2 cells.

 

Heart

One of the popular protocols to generate cardiomyocytes from hPSCs is known as the ‘GiWi’ protocol because it involves the temporal modulation of the Wnt signaling pathway by first, inhibiting glycogen synthase kinase 3 “(GSK-3), followed by WNT. This simple protocol drives cardiac differentiation and is able to produce up to 98% pure functional cardiomyocytes that express cardiac troponin-T (an essential protein for cardiomyocytes to contract) and display sarcomeric organization.

 

Infographic Credit: Nicole Pek

 

Liver

There are numerous protocols available today to differentiate hPSCs into hepatocytes. Ang et al. (2018) and Du et al. (2018) both describe similar strategies to obtain hepatocytes from hPSCs by first driving differentiation into the definitive endoderm lineage, then to hepatic progenitors, and finally to hepatocyte-like cells [9,10]. The differentiated cells express key marker Albumin, an essential protein made by the liver, as well as Carbamoyl-phosphate synthase (CPS1), and Alpha-1 antitrypsin (AAT). These cells were also shown to possess drug metabolism enzyme activities.

 

Pancreas

Pagliuca et al. (2014) reported on a 3D-based method to derive insulin-producing pancreatic beta-cells from hPSCs [11] . This highly-cited protocol also utilizes the step-wise differentiation strategy where hPSCs were patterned into the definitive endoderm lineage, followed by further differentiation into pancreatic progenitors which are subsequently matured into pancreatic beta-cells. These cells were shown to respond to glucose stimulation, resemble human islet beta-cells and reverse hyperglycemia in mice models of diabetes.

 

 

Blood Vessels

Blood vessels are composed of vascular endothelial cells (ECs) and vascular smooth muscle cells (SMCs). There are protocols describing methods to generate both vascular cell types from hPSCs. For example, Narmada et al. (2017) described a method to differentiate ECs from hPSCs by directing cells into the mesodermal lineage under hypoxic conditions [12]. After differentiation, CD31-expressing ECs were purified. These cells are able to form tube-like structures in vitro. While the method generates a more generalized type of ECs, Rosa et al. (2019) recently reported on a method to produce specific subtypes of ECs, namely arterial and venous ECs (from arteries and veins respectively, which are distinct from one another [13]. These differentiated cells display mechanical properties similar to blood vessels.

In 2014, Cheung et al. described a comprehensive approach to generate embryonic origin-specific SMCs from hPSCs in a step-wise fashion, under chemically-defined conditions [14]. hPSCs were first directed into three different lineages – neuroectoderm, lateral plate mesoderm, and paraxial mesoderm. Then, these early precursors were further differentiated into contractile SMCs, thus resulting in the production of lineage-specific SMC subtypes that have different identities and are functionally unique. This is important in the context of disease modeling or even transplantation therapies where the appropriate SMC subtype should be used i.e. for neuroectoderm-SMCs should be used to study/ treat stroke.

Lastly, recently, Wimmer et al (2019) described a method to produce self-organizing human blood vessel organoids from hPSCs cardiac trophonin-T [15]. The organoids contain ECs and pericytes that form well-defined capillary networks enveloped by basement membrane. Post-transplantation, these organoids were also able to engraft into the host animal and form stable, mature, and perfusable vascular networks that are composed of arteries and veins. The blood vessel organoids are able to mimic the structure and function of human blood vessels.

 

What’s Next

Now that the field of stem cell research has reached a significant milestone of establishing robust methods to produce different cells from PSCs in vitro, the next steps are to improve the efficiencies of these methods to increase the purity of differentiated cells. This is critical in ensuring that the PSC-derived cells will be safe and suitable sources of cells for transplantation therapies.

 

About the Author:

Nicole Pek is a
stem cell biologist and enthusiastic science communicator. She has worked on using human pluripotent stem cells
to study cellular development in multiple organ systems, to model complex human diseases, and screen for therapeutics that could treat the diseases. Outside of the lab, Nicole plays a pro-active role in communicating to the public through her science blog ‘Two Cells’ and her education podcast ‘The Diploid Duo’.

 

Suggested Content:

The Case for Investing in Regenerative Medicine in 2021

Scientists now Better Understand Viral Mutations



Preventing the Immune System from Rejecting Gene Therapy

Type 1 Diabetes, Beginning of the End – Close to a Cure (Video)

 

References

 

1. Chambers SM, Fasano CA, Papapetrou EP et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat
Biotechnol 2009;27:275–80.

2. Li Y, Liu M, Yan Y et al. Neural differentiation from pluripotent stem cells: The role of natural and synthetic extracellular matrix. World J Stem Cells 2014;6:11–23.

3. Hong YJ, Do JT. Neural Lineage Differentiation From Pluripotent Stem Cells to Mimic Human Brain Tissues. Front
Bioeng Biotechnol 2019;7, DOI: 10.3389/fbioe.2019.00400.

4. Zhang Y, Pak C, Han Y et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 2013;
78:785–98.

5. Gunhanlar N, Shpak G, van der Kroeg M et
al. A simplified protocol for differentiation of electrophysiologically mature neuronal networks from human induced pluripotent stem cells. Mol
Psychiatry 2018;23:1336–44.

6. Lancaster MA, Knoblich JA. Generation of Cerebral Organoids from Human Pluripotent Stem Cells. Nat Protoc 2014;9:2329–40.

7. Jacob A, Morley M, Hawkins F et al. Differentiation of Human Pluripotent Stem Cells into Functional Lung Alveolar Epithelial Cells. Cell Stem Cell 2017;21:472-488.e10.

8. Miller AJ, Dye BR, Ferrer-Torres D et al. Generation of lung organoids from human pluripotent stem cells in vitro. Nat
Protoc 2019;14:518–40.

9. Ang LT, Tan AKY, Autio MI et al. A Roadmap for Human Liver Differentiation from Pluripotent Stem Cells. Cell
Rep 2018;22:2190–205.

10. Du C, Feng Y, Qiu D et al. Highly efficient and expedited hepatic differentiation from human pluripotent stem cells by pure small-molecule cocktails. Stem Cell Res Ther 2018;9:58.

11. Pagliuca FW, Millman JR, Gürtler M et
al. Generation of functional human pancreatic ? cells in vitro. Cell 2014;
159:428–39.

12. Narmada BC, Goh YT, Li H et al. Human Stem Cell?Derived Endothelial?Hepatic Platform for Efficacy Testing of Vascular?Protective Metabolites from Nutraceuticals. Stem Cells Transl Med 2017;
6:851–63.

13. Rosa S, Praça C, Pitrez PR et al. Functional characterization of iPSC-derived arterial- and venous-like endothelial cells. Sci Rep 2019;9:3826.

14. Cheung C, Bernardo AS, Pedersen RA et
al. Directed differentiation of embryonic origin-specific vascular smooth muscle subtypes from human pluripotent stem cells. Nat Protoc 2014;9:929–38.

15. Wimmer RA, Leopoldi A, Aichinger M et
al. Human blood vessel organoids as a model of diabetic vasculopathy. Nature 2019;565:505–10.

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Seanergy Maritime Holdings Corp. Announces Agreement to Acquire its 16th Capesize Vessel and New Time Charter

Posted on by Admin


Seanergy Maritime Holdings Corp. Announces Agreement to Acquire its 16th Capesize Vessel and New Time Charter

 

GLYFADA, Greece, May 24, 2021 (GLOBE NEWSWIRE) — Seanergy Maritime Holdings Corp. (the “Company”) (NASDAQ: SHIP) announced today that it has entered into a definitive agreement with an unaffiliated third party to purchase a Capesize vessel (the “Vessel”).

The Vessel was built in 2012 at a reputable shipyard in Japan, has a cargo-carrying capacity of approximately 181,000 deadweight tons (“dwt”) and will be renamed M/V Worldship. The Worldship is expected to be delivered within the third quarter of 2021, subject to the satisfaction of certain customary closing conditions. Following her delivery, Seanergy’s fleet will increase to 16 Capesize vessels with an aggregate cargo capacity of approximately 2,800,000 dwt.

The Vessel is fitted with a scrubber and a ballast water treatment system, while the special survey will be completed by the current owner prior to the delivery and, therefore, the Company does not anticipate incurring any off-hire or capital expenditure for this Vessel at least for the next two years.

The purchase price of $33.7 million is expected to be funded with cash on hand and debt financing.

In addition, taking advantage of the current strong market conditions, Seanergy has fixed one of its Capesize vessels, the M/V Patriotship, at $31,000 per day for a period employment of 12-18 months with a major European cargo operator. The contract is expected to commence upon the Patriotship’s upcoming delivery to the Company, which is anticipated in the beginning of June 2021.

Stamatis Tsantanis, the Company’s Chairman & Chief Executive Officer, stated:

“I am very pleased to announce another timely acquisition of a high-quality Capesize vessel built by a renowned shipyard in Japan. The addition of the M/V Worldship to our fleet will further enhance our operating leverage as a leading pure-play Capesize company.

This should be a highly accretive transaction for our shareholders as it will be funded by Seanergy’s strong liquidity, consisting of cash on hand and loan facilities at competitive terms.

Our fleet is currently operating in a decade-high freight environment, where the Capesize forward freight contracts (“FFA”) for the second half of 2021 exceed $30,000 per day. Based on the anticipated delivery of the Vessel in the mid of the third quarter of 2021, the incremental gross revenue from this acquisition may exceed $4 million for the remainder of the year.”

Company fleet upon vessels’ delivery:

Vessel Name Vessel Class Capacity (DWT) Year Built Yard Employment
Partnership Capesize 179,213 2012 Hyundai T/C Index Linked
Championship Capesize 179,238 2011 Sungdong T/C Index Linked
Lordship Capesize 178,838 2010 Hyundai T/C Index Linked
Premiership Capesize 170,024 2010 Sungdong T/C Index Linked
Squireship Capesize 170,018 2010 Sungdong T/C Index Linked
Knightship Capesize 178,978 2010 Hyundai T/C Index Linked
Gloriuship Capesize 171,314 2004 Hyundai T/C Index Linked
Fellowship Capesize 179,701 2010 Daewoo T/C Index Linked
Geniuship Capesize 170,058 2010 Sungdong T/C Index Linked
Hellasship Capesize 181,325 2012 Imabari T/C Index Linked
Flagship Capesize 176,387 2013 Mitsui Engineering T/C Index Linked
Goodship Capesize 177,536 2005 Mitsui Engineering Voyage/Spot
Leadership Capesize 171,199 2001 Koyo – Imabari Voyage/Spot
Tradership* Capesize 176,925 2006 Japanese Shipyard N/A
Patriotship* Capesize 181,709 2010 Japanese Shipyard T/C – $31,000 / day
Worldship** Capesize 181,000 2012 Japanese Shipyard N/A
Total / Average age   2,800,000 11.8    
* deliveries expected by mid-June 2021
** delivery expected in Q3 2021
 

About Seanergy Maritime Holdings Corp.

Seanergy Maritime Holdings Corp. is the only pure-play Capesize ship-owner publicly listed in the US. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. On a ‘fully-delivered’ basis, the Company’s fleet will consist of 16 Capesize vessels with average age of 11.8 years and aggregate cargo carrying capacity of above 2,800,000 dwt.

The Company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP”, its Class A warrants under “SHIPW” and its Class B warrants under “SHIPZ”.

Please visit our company website at: www.seanergymaritime.com.

Forward-Looking Statements

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s operating or financial results; the Company’s liquidity, including its ability to service its indebtedness; competitive factors in the market in which the Company operates; shipping industry trends, including charter rates, vessel values and factors affecting vessel supply and demand; future, pending or recent acquisitions and dispositions, business strategy, areas of possible expansion or contraction, and expected capital spending or operating expenses; risks associated with operations outside the United States; risks associated with the length and severity of the ongoing novel coronavirus (COVID-19) outbreak, including its effects on demand for dry bulk products and the transportation thereof; and other factors listed from time to time in the Company’s filings with the SEC, including its most recent annual report on Form 20-F. The Company’s filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information please contact:

Seanergy Investor Relations
Tel: +30 213 0181 522
E-mail: [email protected]

Capital Link, Inc.
Daniela Guerrero
230 Park Avenue Suite 1536
New York, NY 10169
Tel: (212) 661-7566
E-mail: [email protected]

Higher Vaccinated States Have Experienced Less Foot Traffic

Posted on by Admin 

image credit: OnTheRoxxBand


Are Vaccinated People Spending Differently than those not Vaccinated?

 

With over 20% of the U.S. now having received Covid shots (through April 2021), some interesting statistics have been collected on consumer behavior. There is a slow return to pre-Covid era consumer behavior; this suggests industries impacted most by the quarantines still have much more potential. It also reveals that despite the expectations that the vaccine would encourage many people to be out among others for live music, gym workouts, dining, etc., those that are more likely to be out in crowds are those that have not been vaccinated. This reaction has been as hard to predict as everything else over the past year.

 

Vaccinated Behavior vs. Unvaccinated

According to an April survey by Cardify, the most likely consumers to be out at gyms, restaurants, salons, and entertainment venues are those that have not been vaccinated and don’t plan on getting one. As an explanation as to why those that have received immunities aren’t as likely to be out, Derrick Fung, CEO of Cardify said, vaccinated consumers are “proceeding with cautious optimism.” The vaccinated are slow to behave as they did pre-Covid and are now less comfortable being around large crowds of people.

The Cardify survey data is confirmed by other research conducted by Earnest Research (ER). ER looked at consumer spending and foot traffic across the most and least vaccinated states, along with how well newly acquired customers during COVID have been retained across retailers.

The second report comes to the same conclusion. The vaccine rollouts have not been the big driver of spending outside the home that was expected. Digging deeper to see what is happening, it’s clear the least vaccinated states have experienced the most spending compared to the pre-Covid era. And, states having the most vaccinated have not performed.

For example, Georgia has had the slowest vaccine rollout with just 16% of its population having been “jabbed,” yet the state continues to be an outperformer in total consumer spending and traffic. Massachusetts is the most vaccinated state, with more than 25% of its population having received the precaution, and it is struggling to increase in-person commerce.

 

Source: earnestresearch.com

 

Spending

As demonstrated in the chart above, Massachusetts, with its above-average vaccination rate, has seen its year-on-year spending sitting well below a year earlier. The highest performer Georgia tops the rate of the data points even when Massachusetts is removed from the 25% or greater category. The measure of performance of states with less than 25% inoculated with Georgia removed is still much closer to year-ago traffic than the high vaccine state of Massachusetts. One explanation for the data running counter to what one may have expected is the states with the most in-person traffic are those that had fewer restrictions over the past year. Their citizenry has less re-adaption anxiety and is not uncomfortable mixing with strangers.

Curiously, the states with higher vaccination rates outperformed in the middle of 2020, a lead that narrowed at the end of the year before January’s stimulus-driven uptick and February’s post-stimulus drop. Early March saw an acceleration across all states but without any clear signs of outperformance in the most vaccinated states.

 

Take-Away

Vaccines are not the main economic driver. When it comes to people leaving the perceived protection of their homes to enjoy a show, have their haircut, or enjoy a prepared meal out. What they have become accustomed to may be more telling. For investors, it shows that there is much more potential for increased retail sales for the Covid-recovery stocks such as airlines, restaurants, and gyms. At no place in either the Cardify survey or the Earnest Research report was there a suggestion that the more cautious vaccinated populations would not eventually change over time.

 

Suggested Reading:

Is Inflation Going to Hurt Stocks?

Long Term Retirement Money and Fledgling Companies



Is it Smart to Avoid Brokers that Sell Order Flow?

Are Meme Stocks Improving Flawed Markets?

 

Sources:

https://www.earnestresearch.com/insights/

https://www.cardify.ai/

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Seanergy Maritime Holdings Corp. Announces Agreement to Acquire its 16th Capesize Vessel and New Time Charter

Posted on by Admin


Seanergy Maritime Holdings Corp. Announces Agreement to Acquire its 16th Capesize Vessel and New Time Charter

 

GLYFADA, Greece, May 24, 2021 (GLOBE NEWSWIRE) — Seanergy Maritime Holdings Corp. (the “Company”) (NASDAQ: SHIP) announced today that it has entered into a definitive agreement with an unaffiliated third party to purchase a Capesize vessel (the “Vessel”).

The Vessel was built in 2012 at a reputable shipyard in Japan, has a cargo-carrying capacity of approximately 181,000 deadweight tons (“dwt”) and will be renamed M/V Worldship. The Worldship is expected to be delivered within the third quarter of 2021, subject to the satisfaction of certain customary closing conditions. Following her delivery, Seanergy’s fleet will increase to 16 Capesize vessels with an aggregate cargo capacity of approximately 2,800,000 dwt.

The Vessel is fitted with a scrubber and a ballast water treatment system, while the special survey will be completed by the current owner prior to the delivery and, therefore, the Company does not anticipate incurring any off-hire or capital expenditure for this Vessel at least for the next two years.

The purchase price of $33.7 million is expected to be funded with cash on hand and debt financing.

In addition, taking advantage of the current strong market conditions, Seanergy has fixed one of its Capesize vessels, the M/V Patriotship, at $31,000 per day for a period employment of 12-18 months with a major European cargo operator. The contract is expected to commence upon the Patriotship’s upcoming delivery to the Company, which is anticipated in the beginning of June 2021.

Stamatis Tsantanis, the Company’s Chairman & Chief Executive Officer, stated:

“I am very pleased to announce another timely acquisition of a high-quality Capesize vessel built by a renowned shipyard in Japan. The addition of the M/V Worldship to our fleet will further enhance our operating leverage as a leading pure-play Capesize company.

This should be a highly accretive transaction for our shareholders as it will be funded by Seanergy’s strong liquidity, consisting of cash on hand and loan facilities at competitive terms.

Our fleet is currently operating in a decade-high freight environment, where the Capesize forward freight contracts (“FFA”) for the second half of 2021 exceed $30,000 per day. Based on the anticipated delivery of the Vessel in the mid of the third quarter of 2021, the incremental gross revenue from this acquisition may exceed $4 million for the remainder of the year.”

Company fleet upon vessels’ delivery:

Vessel Name Vessel Class Capacity (DWT) Year Built Yard Employment
Partnership Capesize 179,213 2012 Hyundai T/C Index Linked
Championship Capesize 179,238 2011 Sungdong T/C Index Linked
Lordship Capesize 178,838 2010 Hyundai T/C Index Linked
Premiership Capesize 170,024 2010 Sungdong T/C Index Linked
Squireship Capesize 170,018 2010 Sungdong T/C Index Linked
Knightship Capesize 178,978 2010 Hyundai T/C Index Linked
Gloriuship Capesize 171,314 2004 Hyundai T/C Index Linked
Fellowship Capesize 179,701 2010 Daewoo T/C Index Linked
Geniuship Capesize 170,058 2010 Sungdong T/C Index Linked
Hellasship Capesize 181,325 2012 Imabari T/C Index Linked
Flagship Capesize 176,387 2013 Mitsui Engineering T/C Index Linked
Goodship Capesize 177,536 2005 Mitsui Engineering Voyage/Spot
Leadership Capesize 171,199 2001 Koyo – Imabari Voyage/Spot
Tradership* Capesize 176,925 2006 Japanese Shipyard N/A
Patriotship* Capesize 181,709 2010 Japanese Shipyard T/C – $31,000 / day
Worldship** Capesize 181,000 2012 Japanese Shipyard N/A
Total / Average age   2,800,000 11.8    
* deliveries expected by mid-June 2021
** delivery expected in Q3 2021
 

About Seanergy Maritime Holdings Corp.

Seanergy Maritime Holdings Corp. is the only pure-play Capesize ship-owner publicly listed in the US. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. On a ‘fully-delivered’ basis, the Company’s fleet will consist of 16 Capesize vessels with average age of 11.8 years and aggregate cargo carrying capacity of above 2,800,000 dwt.

The Company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP”, its Class A warrants under “SHIPW” and its Class B warrants under “SHIPZ”.

Please visit our company website at: www.seanergymaritime.com.

Forward-Looking Statements

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s operating or financial results; the Company’s liquidity, including its ability to service its indebtedness; competitive factors in the market in which the Company operates; shipping industry trends, including charter rates, vessel values and factors affecting vessel supply and demand; future, pending or recent acquisitions and dispositions, business strategy, areas of possible expansion or contraction, and expected capital spending or operating expenses; risks associated with operations outside the United States; risks associated with the length and severity of the ongoing novel coronavirus (COVID-19) outbreak, including its effects on demand for dry bulk products and the transportation thereof; and other factors listed from time to time in the Company’s filings with the SEC, including its most recent annual report on Form 20-F. The Company’s filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information please contact:

Seanergy Investor Relations
Tel: +30 213 0181 522
E-mail: [email protected]

Capital Link, Inc.
Daniela Guerrero
230 Park Avenue Suite 1536
New York, NY 10169
Tel: (212) 661-7566
E-mail: [email protected]

Release – The Sun Sentinel Names TherapeuticsMD Inc a Winner of the South Florida Top Workplaces 2021 Award

Posted on by Admin


The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award

 

BOCA RATON, Fla.–(BUSINESS WIRE)–May 24, 2021– 
TherapeuticsMD, Inc. (NASDAQ: TXMD), has been awarded a Top Workplaces 2021 honor by 
The Sun Sentinel. The list is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner Energage, LLC. The anonymous survey uniquely measures 15 culture drivers that are critical to the success of any organization including alignment, execution, and connection.

“During this very challenging time, Top Workplaces has proven to be a beacon of light for organizations, as well as a sign of resiliency and strong business performance,” said  Eric Rubino, Energage CEO. “When you give your employees a voice, you come together to navigate challenges and shape your path forward. Top Workplaces draw on real-time insights into what works best for their organization, so they can make informed decisions that have a positive impact on their people and their business.”

“I’m incredibly proud of the employees in the 
TherapeuticsMD family. Winning this amazing award is a testament to the culture we have built and maintain– entrepreneurial, respectful, focused on success, and dedicated to our mission of advancing women’s health and improving therapeutic options for women,” said  Robert G. Finizio, Chief Executive Officer of 
TherapeuticsMD. “Getting through these difficult pandemic months has made us all appreciate the value of working with purpose and working together to create a great future for our organization.”

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about 
TherapeuticsMD, please visit therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: 
TherapeuticsMD.

About Energage

Making the world a better place to work together.™

Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 14 years of culture research and the results from 23 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit energage.com or topworkplaces.com.

Forward-Looking Statements

This press release by 
TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the 
Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; whether the company will be able to successfully divest its vitaCare business and how the proceeds that may be generated by any such divestiture will be utilized; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; whether the FDA will approve the lower dose of BIJUVA; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership.

Investor Contacts
Nichol Ochsner
Vice President, Investor Relations
561-961-1900, ext. 2088
[email protected]

In-Site Communications, Inc.
Lisa M. Wilson
212-452-2793
[email protected]

Media Contact
Kristen Landon
Vice President, 
Marketing and Corporate Communications
561-961-1900
[email protected]

Source: 
TherapeuticsMD, Inc.

Release – Esports Entertainment Groups New Jersey Gaming License Application Accepted by the NJ DGE

Posted on by Admin

 


Esports Entertainment Group’s New Jersey Gaming License Application Accepted by the NJ DGE

 

Newark, New Jersey–(Newsfile Corp. – May 24, 2021) – Esports Entertainment Group, Inc. (NASDAQ: GMBL) (NASDAQ: GMBLW) (or the “Company”) is proud to announce that its subsidiary GMBL has been notified by the New Jersey Division of Gaming Enforcement (DGE) that its application has been formally accepted by the DGE. This acceptance allows the company to submit its software to the DGE testing lab and apply for a Transactional Waiver. The company expects to complete this process and be live taking bets in the state by the end of its Fiscal 1Q.

“This is a major step for us in our growth strategy in the US,” commented Grant Johnson, CEO of Esports Entertainment Group. “According to a study from data firm Interpret, over 50% of U.S. esports fans said they are likely to engage in esports betting so we are confident that demand will be strong”, continued Johnson. “Securing access to what is currently the largest market for sports betting in the US is very exciting. We are also in discussions with partners and regulators in additional jurisdictions to continue our expansion plans.”

New Jersey won a U.S. Supreme Court case in 2018 allowing all 50 states to offer legal sports betting should they so choose. It quickly dominated the East Coast market and challenged Nevada for the national lead. With a solid regulatory framework based on player protection, business stability, and growth, the New Jersey gaming industry has enjoyed exceptional growth in recent years.

About Esports Entertainment Group

Esports Entertainment Group, Inc. is an esports and iGaming company. The Company maintains offices in New Jersey, the UK and Malta. For more information visit www.esportsentertainmentgroup.com.

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact:

U.S. Investor Relations
RedChip Companies, Inc.
Dave Gentry
407-491-4498
[email protected]

Media & Investor Relations Inquiries
[email protected]

Orion Group Holdings (ORN) – Awards Building – New Concrete Awards of 17 million

Posted on by Admin

Monday, May 24, 2021

Orion Group Holdings (ORN)
Awards Building – New Concrete Awards of $17 million

Orion Group Holdings, based in Houston, Texas, is a specialty construction company within the Marine and Industrial Construction sectors, with operations focused in the continental United States and Caribbean. Revenue is split roughly 50/50 between a Marine Construction segment that provides marine facility, pipeline and structural construction services and a Commercial Concrete segment that provides turnkey concrete services in the light commercial and structural construction markets.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New awards for $17 million in Concrete announced late last week. The Galveston work highlights the collaboration potential of the Concrete and Marine divisions working together. First award is $5.5 million from Hensel Phelps for concrete services for the new Royal Caribbean Cruise Terminal in the Port of Galveston. Paving and tilt-wall construction work should start shortly with completion this year. Second award is $6.5 million for construction of four tilt-wall buildings and associated paving in San Antonio that will begin in 3Q2021 with completion this year. Third award is $5.1 million for construction of multiple tilt-wall buildings and site paving for a new business park NW of the DFW area. The work should begin in 3Q2021 and run into 2Q2022.

    Maintain 2021E EBITDA of $47.0 million, including asset sales of $1.6 million.  Tough comps are ahead, but Marine results should pick up and Concrete has upside potential. 1Q2021 backlog of $365 million dropped for both Marine and Concrete, but low bids pending award of $134 million increased $38 million so potential backlog remains high at $499 million. Recent awards appear to be incremental to …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.